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1. Introduction
Stents have substantially improved the safety and efficacy of percutaneous revascularization
of atherosclerotic coronary arteries. The attendant risk of emergency referral for Coronary
artery bypass graft surgery ( CABG ) and the need for subsequent revascularization procedures
have been reduced by more than 50% since the use of new generation stents i.e drug eluted
stents ( DES ) starting 2002. Comparisons of Percatouneous coronary intervention ( PCI ) and
CABG have been made in 7 randomized trials designed to identify the most effective alterna‐
tive for selected patients with multivessel CAD of whom both methods were deemed feasible.
[1,2]. The individual results of these trials and a meta-analysis of their combined results have
consistently shown equivalent survival rates with use of the 2 strategies over approximately
5 years of follow-up.
2. Coronary artery bypass graft surgery
A coronary artery bypass surgery is a surgical procedure performed to relieve angina and
reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the
patient's body are grafted to the coronary arteries to bypass atherosclerotic narrowings and
improve the blood supply to the coronary circulation supplying the myocardium (heart
muscle). Example, Left internal mammary artery (LIMA) graft to LAD and SVG to OM and
RCA (figure 1). The operation is usually performed with the heart stopped, requiring the usage
of cardiopulmonary bypass; other methods are available to achieve CABG on a beating heart,
so-called "off-pump" surgery. [3].
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3. Advantages of CABG
Over the last 4 decades, surgical coronary artery revascularization techniques and technology
have advanced significantly. As a result, despite an increasingly older and sicker patient
population, CABG outcomes continue to improve. For example, the predicted mortality of
CABG patients has increased steadily over the past decade, yet observed operative mortality
rates have decreased, [4]. This is partly because advances in preoperative evaluation, including
more precise coronary artery and myocardial imaging and diagnostic techniques, have
allowed more appropriate patient selection and surgical planning. In addition, preoperative,
intraoperative, and postoperative monitoring and therapeutic interventions have made CABG
safer, even for critically ill and high-risk patients. Improvements in cardiopulmonary perfu‐
sion and careful myocardial protection, as well as the use of off-pump and on-pump beating-
heart techniques in selected patients, have also decreased perioperative morbidity and
mortality rates. [5,6].
Use of the bilateral IMAs offers the possibility of constructing various configurations, making to‐
tal arterial myocardial revascularisation possible with a minimum number of arterial conduits.
Use of the skeletonised RIMA through the transverse sinus and eventually retrocavally can reach
most branches of the circumflex system and is associated with an excellent patency rate. Patients
who received bilateral IMA grafts for left coronary system revascularisation had improved ear‐
ly and late outcomes and decreased risk of death, reoperation, and angioplasty. [7].
Figure 1. CT coronary angiogram, showing a CABG done 5 years ago with LIMA to LAD artery and SVG to OM and
RCA.
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4. Percutaneous coronary intervention using drug eluted stents
Percutaneous coronary intervention (PCI) involves dilatation of an obstructed or narrowed
coronary artery, using a balloon catheter to dilate the artery from within. After balloon
dilatation, a stainless steel stent is usually placed in the coronary artery. Antiplatelet agents
like aspirin or clopidogrel are mandatory to be used after stenting. Stents may be either bare
metal (BMS) or drug-eluting stents (DES). Indications for PCI might be elective or emergency
according to the clinical presentations of the patients. Primary PCI in the setting of ST segment
elevation myocardial infarction (STEMI): When the catheterization lab including the team and
facility is available, angioplasty with stenting is the optimal method of reperfusion for STEMI.
The target "door to balloon time" is 90 minutes, [8]. Rescue PCI is considered as a treatment in
patients with thrombolysis - if there is failure to reperfuse, further ischaemia with persistant
chest pain, or continuous ST elevation. PCI is considered also as an early invasive strategy in
Acute coronary syndrome, Non-ST elevation myocardial infarction (NSTEMI) and unstable
angina: [9]., or conservative strategy for patients who are at medium-to-high risk of subsequent
cardiac events. Elective PCI for patient with Stable angina or positive stress test: with single
or double vessel disease, where optimal medical therapy fails to control symptoms. Patients
with triple vessel disease, who are unsuitable for CABG, [10].
Figure 2. Cypher Stent- Siroliums eluted stent
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A drug-eluting stent presents or releases single or multiple bioactive agents into the blood
stream. The drug can deposit in and/or affect blood vessels, cells, plaque, or tissues either
adjacent to the stent or at a distance. The drug can be embedded and released from within
(“matrix-type”) or surrounded by and released through (“reservoir-type”) polymer materials
that coat (“strut-adherent”) or span (“strut-spanning”) the struts of the stents. These agents
prevent in-stent restenosis by reducing the intimal hyperplasia, [11].
The advantages and a lower cost compared to CABG makes DES an attractive option to treat
coronary artery disease. Currently, five DESs are available in the USA: the CYPHER sirolimus-
eluting stent from Cordis (approved by FDA on 24 April 2003), Figure 2, 3. The TAXUS Express
and Liberté paclitaxel-eluting stents from Boston Scientific (approved by FDA on 4 March 2004
and 10 October 2008, respectively) (TAXUS Express is referred to as TAXUS) Figure 4, the
ENDEAVOR zotarolimus-eluting stent from Medtronic (approved by FDA on 1 February
2008), and the XIENCE V Figure 5, everolimus-eluting stent from Abbott Vascular (approved
by FDA on 2 July 2008). [12].
Figure 3. Complex case with LM disease treated by 2 Cypher stents
Figure 4. Taxus stent-Paclitaxal eluted stent
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Figure 5. Significan disease of proximal RCA treated by Xience stent
5. Outcomes of coronary-artery bypass grafting versus bare metal stent
implantation
The New York's cardiac registries were one of the largest studies which identify 37,212 patients
with multivessel disease who underwent CABG and 22,102 patients with multivessel disease
who underwent PCI using BMS from January 1, 1997, to December 31, 2000. They determined
the rates of death and subsequent revascularization within three years after the procedure in
various groups of patients according to the number of diseased vessels and presence or absence
of involvement of the left anterior descending coronary artery LAD.
Risk-adjusted survival rates were significantly higher among patients who underwent CABG
than among those who received a stent in all of the anatomical subgroups studied. For example,
the adjusted hazard ratio for the long-term risk of death after CABG relative to stent implan‐
tation was 0.64 (95 percent confidence interval, 0.56 to 0.74) for patients with three-vessel
disease with involvement of the proximal LAD and 0.76 (95 percent confidence interval, 0.60
to 0.96) for patients with two-vessel disease with involvement of the non-proximal LAD. Also,
the three-year rates of revascularization were considerably higher in the stenting group than
in the CABG group (7.8 percent vs. 0.3 percent for subsequent CABG and 27.3 percent vs. 4.6
percent for subsequent PCI), [13].
Texas Heart Institute Cardiovascular Research Database retrospectively identified patients
who had undergone their 1st revascularization procedure with coronary artery bypass surgery
(CABG; n=2,826) or coronary stenting (n=2,793) between January 1995 and December 1999.
They have found that in-hospital mortality was significantly greater in patients undergoing
CABG than in those undergoing stenting (3.6% vs 0.75%; adjusted OR 8.4; P <0.0001). At a
mean 2.5-year follow-up, risk-adjusted survival was equivalent (CABG 91%, stenting 95%;
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adjusted OR 1.26; P = 0.06). When subgroups matched for severity of disease were compared,
no differences in risk-adjusted survival were seen, [14].
6. Drug-eluting stents vs coronary artery bypass surgery for the treatment
of multivessel coronary disease
A Chinese  study identified  3720  consecutive  patients  with  multivessel  disease  who un‐
derwent  isolated  CABG  surgery  or  received  drug-eluting  stents  between  April  1,  2004,
and  December  31,  2005,  which  compared  safety  (total  mortality,  myocardial  infarction,
and stroke) and efficacy (target-vessel revascularization) during a 3-year follow-up. These
outcomes were compared after adjustment for the differences in baseline risk factors. Pa‐
tients who underwent CABG (n=1886) were older and had more comorbidities than pa‐
tients  who  received  drug-eluting  stents  (n=1834).  Patients  receiving  drug-eluting  stents
had  considerably  higher  3-year  rates  of  target-vessel  revascularization.  Drug-eluting
stents  were  also  associated with higher  rates  of  death (adjusted hazard ratio,  1.62;  95%
confidence  interval,  1.07  to  2.47)  and myocardial  infarction (adjusted hazard ratio,  1.65;
95% confidence interval, 1.15 to 2.44). The risk adjusted rate of stroke was similar in the
2 groups (hazard ratio, 0.92; 95% confidence interval, 0.69 to 1.51). [15]
In a Korean study, a 5-year clinical follow-up of 395 patients with unprotected LMCA disease
who underwent PCI with drug-eluting stents (DES) (n = 176) or CABG (n = 219) was preformed
from January 2003 to May 2004. In the 5-year follow-up, cohort of DES and concurrent CABG,
there had not been a significant difference in the adjusted risk of death (HR: 0.83; 95% CI: 0.34
to 2.07; p = 0.70) or the risk of the composite outcome (HR: 0.91; 95% CI: 0.45 to 1.83; p = 0.79).
The rates of TVR were also higher in the DES group than the CABG group (HR: 6.22; 95% CI:
2.26 to 17.14; p < 0.001), [16].
In an Italian study, 249 patients: 107 of whom were treated with PCI along with DES im‐
plantation  and  142  treated  with  CABG.  At  5-year  clinical  follow-up,  no  difference  was
found between PCI  and CABG in  the  occurrence  of  cardiac  death  (adjusted  odds  ratio
[OR]: 0.502; 95% confidence interval [CI]: 0.162 to 1.461; p = 0.24). The PCI group showed
a trend toward a lower occurrence of the composite end point of cardiac death and MI
(adjusted OR: 0.408; 95% CI: 0.146 to 1.061; p = 0.06). Percutaneous coronary intervention
was associated with a lower rate of the composite end point of death, MI, and/or stroke
(OR:  0.399;  95% CI:  0.151  to  0.989;  p  =  0.04).  Indeed,  CABG was  correlated with  lower
target  vessel  revascularization (adjusted OR:  4.411;  95% CI:  1.825 to  11.371;  p  =  0.0004).
No difference was detected in the occurrence of major adverse cardiac and cerebrovascu‐
lar events (adjusted OR: 1.578; 95% CI: 0.825 to 3.054; p = 0.18) [17].
In a Meta-analysis of clinical studies comparing CABG with DES in patients with unpro‐
tected left  main  coronary  artery  narrowing,  the  analysis  included 2,905  patients  from 8
clinical studies (2 randomized trials and 6 nonrandomized studies).  At 1-year follow-up,
there  was  no  significant  difference  between  the  CABG and DES groups  in  the  risk  for
death (odds ratio  [OR] 1.12,  95% confidence interval  [CI]  0.80 to 1.56)  or  the composite
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end point  of  death,  myocardial  infarction,  or  stroke (OR 1.25,  95% CI 0.86 to 1.82).  The
risk for target  vessel  revascularization was significantly lower in the CABG group com‐
pared to  the  PCI group (OR 0.44,  95% CI  0.32  to  0.59).  In  conclusion,  PCI  with DES is
safe and could represent a good alternative to CABG for selected cases in patients with
ULMCA disease, [18].
In  the  SYNTAX trial,  1,800  patients  with  three-vessel  and/or  LM disease  were  random‐
ized  to  either  CABG  or  PCI;  of  these,  271  LM patients  were  prospectively  assigned  to
receive  a  15-month angiogram.  The primary endpoint  for  the  CABG arm was  the  ratio
of  ≥50%  to  <100%  obstructed/occluded  grafts  bypassing  LM  lesions  to  the  number
placed.  The  primary  endpoint  for  the  PCI  arm  was  the  proportion  of  patients  with
≤50%  diameter  stenosis  ('patent'  stents)  of  treated  LM  lesions.  Per  protocol,  no  formal
comparison between CABG and PCI arms was intended based on the differing primary
endpoints.  Available  15-month  angiograms  were  analyzed  for  114  CABG  and  149  PCI
patients.  At 15 months, 9.9% (26/263) of CABG grafts were 100% occluded and an addi‐
tional  5.7%  (15/263)  were  ≥50%  to  <100%  occluded.  Overall,  27.2%  (31/114)  of  patients
had ≥1  obstructed/occluded graft.  The  15-month CABG MACCE rate  was  8.8% (10/114)
and MACCE at  15 months was not  significantly associated with graft  obstruction/occlu‐
sion (p=0.85).  In the PCI arm, 92.4% (134/145) of patients had ≤50% diameter LM steno‐
sis  at  15  months  (89.7%  [87/97]  distal  LM  lesions  and  97.9%  [47/48]  non-distal  LM
lesions).  The  15-month  PCI  MACCE rate  was  12.8% (20/156)  and  this  was  significantly
associated with lack of stent patency at 15 months (p<0.001), mainly due to repeated re‐
vascularization.  [19].
The results of the SYNTAX trial confirm that at 3 years CABG remains the treatment of choice
for most patients with three-vessel and LMS disease and especially in those with the most
severe disease. SYNTAX will have a profound effect on practice recommendations for the
foreseeable future and has already had a major effect on the new European Society for
Cardiology/European Association for Cardiothoracic Surgery guidelines for myocardial
revascularization, [20].
At four years follow-up of SYNTAX trial which presented at TCT in 2011, there was no
difference in MACCE between CABG and PCI in those with a SYNTAX score of 0 to 22, (26.1%
vs 28.6%; p=0.57). This is good, and would legitimize the use of PCI in this kind of patient".
But for those with an intermediate SYNTAX score of 23 to 32, "You see immediately a highly
significant difference" in MACCE rate (21.5% for CABG vs 32% for PCI; p=0.006). For those
with a high SYNTAX score (≥33), "mortality is double in the PCI group compared with CABG
(16.1% vs 8.4%; p=0.04) in addition to MI is two to three times higher with PCI than with CABG
(9.3% vs 3.9%; p=0.01).
In this highest-risk group, even the end point of death/stroke/MI becomes significantly higher
with PCI, (22.7% vs 14.6%; p=0.01), and MACCE were much higher (40.1% vs 23.6%; p<0.001),
driven in large part by a 17% higher rate of revascularization in this high-risk group at four
years. Figures 6& 7
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Figure 6. years follow up in Syntax study, demonstrate all cause death/CVA/MI up to 4 years
Figure 7. years follow up in Syntax study, demonstrate all cause death up to 4 years
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7. Revascularization for patients with diabetes mellitus and multivessel
CAD
In the BARI 2D trial, the selected revascularization strategy, CABG or PCI, was based on
physician discretion, declared independent of randomization to either immediate or deferred
revascularization if clinically warranted. They analyzed factors favoring selection of CABG
versus PCI in 1,593 diabetic patients with multivessel CAD enrolled between 2001 and 2005.
The majority of diabetic patients with multivessel disease were selected for PCI rather than
CABG. Preference for CABG over PCI was largely based on angiographic features related to
the extent, location, and nature of CAD, as well as geographic, demographic, and clinical
factors. [21]
However, with each intervention the benefit is less and the risks and complications are greater
than in patients without diabetes. Revascularization for treatment of ST elevation myocardial
infarction increases survival. Both interventions relieve symptoms, but neither improves
survival except in patients at high risk. In patients with clinically stable chronic coronary
disease, survival after CABG or PCI is comparable with that in patients treated with optimal
medical therapy alone. Accordingly, evaluation for revascularization can be deferred until
signs and symptoms worsen except in patients at high risk. In patients at high risk survival
after promptly implemented CABG is greater than that with optimal medical therapy,
especially when the diabetes is being treated with insulin sensitizing agents. [22]
8. Quality of life after PCI with DES or CABG
Among patients with three-vessel or left main coronary artery disease who were suitable
candidates for either PCI using DES or CABG, both strategies resulted in significant relief from
angina and improvements in overall health status over the first year of follow-up. At both 6
and 12 months, there was a small but significant reduction in angina frequency with CABG as
compared with PCI in the overall population. These symptomatic benefits of CABG were
counterbalanced by the more rapid recovery and improved short-term health status achieved
with PCI. [23]
9. Future study with the second generation des and other bioabsorbable
stents
EXCEL is a 2600-patient study comparing patients with left main disease randomized to bypass
surgery or PCI with the Xience stent and followed for at least three years. The primary end
point is death, stroke, and MI; repeat revascularization is a secondary end point. EXCEL results
awaited. Figure (8)
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Figure 8. EXCEL study protocol comparing Xience stent with CABG
Figure 9. Absorb Stent- Bioabsorbale everolimus eluted stent
Stents composed of bioabsorbable/biodegradable materials represent an attractive alternative
revascularization modality; the justification stems from the short-term need for vessel scaffold‐
ing and avoidance of the potential long-term complications of metallic stents. Compared with
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metallic stents, there are several potential advantages, including complete absorption of stent
material, [24], Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold
System"These outcomes suggest that a temporary scaffold like ABSORB provides durable re‐
sults over the long term and a permanent implant may not be necessary to effectively treat pa‐
tients with coronary artery disease". ABSORB II trial is ongoing. Figure (9)
10. Combining the best of both worlds hybrid coronary revascularization
As PCI technology improves and techniques of LIMA-to-LAD grafting become less invasive,
hybrid coronary revascularization is becoming a distinct possibility. For example, a minimally
invasive, off-pump, direct LIMA-to-LAD anastomosis can be combined with DES placement
in a focal mid-right-coronary-artery lesion in a patient with complex proximal LAD lesions.
Hybrid coronary revascularization procedures are currently being performed, with promising
early results. A few centers, now have hybrid operating rooms with cardiac surgical and
coronary angiographic capabilities that make it possible to perform simultaneous hybrid
coronary revascularizations. Staged hybrid revascularizations are performed in standard
catheterization laboratories and operating rooms. [25,26].
11. Conclusion
Each strategy can have great outcomes in appropriately selected patients. Hard clinical
outcomes (death/MI/CVA) are generally similar, need to weigh the risk of potential repetition
of procedures with PCI using DES vs. the greater morbidity of CABG. The 3VD and LMCA
Disease are high-risk coronary lesions and the least stable subtypes of “stable CAD” PCI and
CABG have very similar rates of hard clinical endpoints. Greater rates of recurrent revascu‐
larization with PCI, especially in complex disease, Patient selection and patient preference will
generally dictate the best and most appropriate care. The so-called SYNTAX score, evolved
for the trial, offers a grading system, based on patient anatomy, to help surgeons and inter‐
ventionalists make this decision. As PCI and CABG are refined further, surgeons and cardi‐
ologists will no doubt learn to use these improved interventional techniques and surgical
procedures in a way that will optimize the treatment of each individual patient.
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